42 completed, 7 unknown, 6 terminated, 5 recruiting. 24 Phase 2, 18 Phase 1, 16 Phase 3, 8 Phase 4, 5 Not applicable.
Follow Finasteride: new trials by email Literature Review of Finasteride trials Research Report on Finasteride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 / Phase 3 | Not yet recruiting | VA Office of Research and Development | 300 | 2027-10-01 | 2026-08-04 |
| Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia Finasteride 5 mg Tablet, single dose, Tamsulosin 0.4Mg Capsule - Benign Prostatic Hyperplasia | Phase 3 | Not yet recruiting | Il-Yang Pharm. Co., Ltd. | 660 | 2026-11-09 | 2026-10-13 |
| Finasteride and Cutibacterium Finasteride 1 mg, Placebo Control - Dihydrotestosterone, Periprosthetic Joint Infection (PJI) | Phase 4 | Not yet recruiting | University of Washington | 40 | 2026-08-31 | 2026-07-28 |
| New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia raloxifene, Finasteride - BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 242 | 2025-12-03 | 2026-03-23 |
| Various Procedural Treatment Options for Androgenetic Alopecia topical finasteride, Topical minoxidil - Androgenetic Alopecia | Phase 2 | Not yet recruiting | Sheikh Zayed Medical College | 190 | 2025-02-01 | 2025-02-13 |
| Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia minoxidil + finasteride, Placebo foam - Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA) | Phase 2 | Completed | Beijing Dayspring Pharmaceutical Technology Co., Ltd | 110 | 2024-12-05 | 2026-03-03 |
| Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss Aminexil® active+ lotion, Finasteride 1mg - Androgenetic Alopecia | Not applicable | Unknown | Cosmetique Active International | 140 | 2024-11-02 | 2024-09-19 |
| Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia Finasteride, Minoxidil - Androgenetic Alopecia | Phase 2 / Phase 3 | Unknown | Universitas Indonesia | 40 | 2023-05-01 | 2023-09-22 |
| Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia Finlândia Association + finasteride placebo, Minoxidil + finasteride - Androgenetic Alopecia | Phase 3 | Recruiting | EMS | 190 | 2023-02-02 | 2025-12-08 |
| Prostate Medication, Metabolism and Gut Microbiota Prostate hyperplasia medication, LhRH-antagonist - Prostatic Hyperplasia, Prostate Cancer | Phase 4 | Recruiting | Turku University Hospital | 100 | 2022-12-01 | 2023-08-21 |
| Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia FOL100, Propecia 1Mg Tablet - Androgenic Alopecia | Phase 1 | Unknown | Follicle Pharma Ltd | 90 | 2022-10-20 | 2024-03-07 |
| A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 Finasteride 1mg Tablet, IVL3001 - Androgenetic Alopecia | Phase 1 / Phase 2 | Completed | Inventage Lab., Inc. | 40 | 2021-09-21 | 2022-03-04 |
| 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy Finasteride - Benign Prostatic Hyperplasia, Prostate Hyperplasia | Not applicable | Recruiting | Beth Israel Deaconess Medical Center | 120 | 2020-09-25 | 2025-10-28 |
| Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) GV1001 placebo, Proscar placebo - Benign Prostatic Hyperplasia (BPH) | Phase 3 | Completed | GemVax & Kael | 423 | 2019-10-30 | 2022-08-25 |
| The Effect of Pre-operative Use of Finasteride Versus Cyproterone Acetate on Blood Loss With Transurethral Resection of Prostate cyproterone acetate, finasteride, no treatment received - Prostate Hyperplasia | Early Phase 1 | Completed | Benha University | 60 | 2019-07-01 | 2021-07-21 |
| Testosterone Plus Finasteride Treatment After Spinal Cord Injury Testosterone Enanthate, Finasteride, Placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 | Terminated | VA Office of Research and Development | 33 | 2017-04-27 | 2023-09-29 |
| Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia P-3074, Finasteride, P-3074 Vehicle - Alopecia, Androgenetic | Phase 3 | Completed | Polichem S.A. | 458 | 2016-08-02 | 2019-06-20 |
| The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia 5% Minoxidil, 200mg Spironolactone, 5mg Finasteride - Female Androgenetic Alopecia | Phase 4 | Withdrawn | University of Florida | 2016-08-01 | 2016-09-02 | |
| A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males Setipiprant, Placebo, Finasteride - Alopecia | Phase 2 | Completed | Allergan | 169 | 2016-07-14 | 2019-04-05 |
| H-36731: Finasteride in Management of Elevated Red Blood Cells Finasteride - ERYTHROCYTOSIS | Phase 3 | Withdrawn | Baylor College of Medicine | 2016-02-01 | 2019-12-16 |
Showing 20 of 68. Sign in to see all of them.
Prostatic Hyperplasia (21) · Alopecia (13) · Prostatic Neoplasms (9) · Central Serous Chorioretinopathy (3) · Hypogonadism (3) · Retinal Diseases (3) · Bone Resorption (2) · Central Nervous System Diseases (2) · Endocrine System Diseases (2) · Genital Diseases, Male (2) · Gonadal Disorders (2) · Motor Activity (2) · Nervous System Diseases (2) · Spinal Cord Diseases (2) · Spinal Cord Injuries (2)
Dr. Reddy's Laboratories Limited (4) · VA Office of Research and Development (4) · National Eye Institute (NEI) (3) · University of Washington (3) · Actavis Inc. (2) · Beth Israel Deaconess Medical Center (2) · GlaxoSmithKline (2) · Mylan Pharmaceuticals Inc (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Organon and Co (2) · Teva Pharmaceuticals USA (2) · Allergan (1) · Alliance for Clinical Trials in Oncology (1) · Baylor College of Medicine (1) · Beijing Dayspring Pharmaceutical Technology Co., Ltd (1)
United States (32) · Canada (9) · South Korea (3) · Belgium (2) · Brazil (2) · France (2) · Germany (2) · Italy (2) · Russia (2) · Argentina (1) · Australia (1) · China (1) · Egypt (1) · Finland (1) · Greece (1)
Benoit Girard, M.D. (2) · Darin B. Brimhall (2) · Dorian Williams, M.D. (2) · Gaetano Morelli, MD (2) · Joshua F Yarrow, PhD MS BS (2) · So Ran Hong, M.D. (2) · Andrea De Censi, MD (1) · Antonio Finelli, MD MSc FRCSC (1) · Aria F. Olumi, MD (1) · Aria Olumi, MD (1) · Catherine B Meyerle, MD (1)
PMID 11796283, PMID 12689743, PMID 14681504, PMID 17196507, PMID 20378927, PMID 20969601, PMID 21273946, PMID 24012740, PMID 24326421, PMID 25353053, PMID 30300367, PMID 32969781, PMID 34709067, PMID 38833144, PMID 39722695, PMID 40522203, PMID 40683564
K23HD045386 (2), I01RX001449 (1), N01CN35159 (1), P30CA016672 (1), R01CA138627 (1), R01DK124502 (1), R01DK142211 (1), U01DK046472 (1), U01DK060817 (1), U10CA031946 (1), U54HD042454 (1)